• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

FDA's $6.4 Billion Plan for Quick Reviews Moves to Senate

Article

Mylan Inc.

(MYL)

Pfizer Inc. (PFE)

A $6.4 billion effort to speed U.S. reviews of new drugs and medical devices is a step closer to law as the agreements , and other companies struck with regulators wind through Congress.

The Senate is set to begin voting as soon as today on more than $2 billion in new fees that drug and device companies will pay regulators through 2017 to review products for safety and efficacy. The figure includes $1.56 billion from generic-drug companies such as Canonsburg, Pennsylvania-based Mylan, which had been exempt from such fees.

Read the full story: http://hcp.lv/MB3OCO

Source: Bloomberg

Related Videos
4 experts in this video
4 experts in this video
Rakendu Rajendran, MBBS
Vivek Bhalla, MD, Stanford University School of Medicine
Dr Carla Nester
Rayan Salih, MD, Northeast Georgia Health System
Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, Mount Sinai Fuster Heart Hospital
AJMC interview with Ali Shan Hafeez and Dr Abdul Rafae Faisal | Background image credit: ipopba - stock.adobe.com
Varsha Tanguturi, MD, MPH, Mass General Hospital
 Khush Kharidia, MD, UT Southwestern
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.